Yumanity Therapeutics, a clinical-stage biopharmaceutical company, completed the acquisition of Kineta, a private immuno-oncology company, for $69m. “Closing the reverse merger with Yumanity and the PIPE financing round provides Kineta with the capital necessary to advance our lead program, KVA12123, into clinical development in cancer patients. We remain on track to report interim safety and efficacy data for KVA12123 in patients with advanced solid tumors in late 2023. We greatly appreciate the support of our investors as we continue to deliver on our mission of developing next-generation immunotherapies that transform patients’ lives," Shawn Iadonato, Kineta CEO.